You are here

Open

Reset

NOTE: The Solicitations and topics listed on this site are copies from the various SBIR agency solicitations and are not necessarily the latest and most up-to-date. For this reason, you should visit the respective agency SBIR sites to read the official version of the solicitations and download the appropriate forms and rules.


If no search results for your keyword(s) were found, you are encouraged to review Agency omnibus solicitations for additional funding opportunities. Omnibus solicitations are structured to be broad, extensive Programmatic issuances with research areas related to the petitioning Agency and are not limited to predetermined Topics/Subtopics. If upon reviewing you have additional questions, you may consider reaching out to the respective Agency for clarification regarding acceptable proposals (https://www.sbir.gov/agency-contacts).

  1. NIH/NIAID 105: Adjuvant Development for Vaccines and for Autoimmune and Allergic Diseases

    Release Date: 07-12-2021Open Date: 07-12-2021Due Date: 10-28-2021Close Date: 10-28-2021

    Fast-Track proposals will be accepted. Direct-to-phase II proposals will be accepted. Page 109 Number of anticipated awards: 1-3 Budget (total costs): Phase I: $300,000/year for up to 2 years; Phase II: $1,000,000/year with appropriate justification by the applicant for up to 3 years. Background The goal of this program is to support the preclinical development of novel vaccine adjuvants for use ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  2. NIH/NIAID 104: Adjuvant Discovery for Vaccines and for Autoimmune and Allergic Diseases

    Release Date: 07-12-2021Open Date: 07-12-2021Due Date: 10-28-2021Close Date: 10-28-2021

    Fast-Track proposals will be accepted. Direct-to-phase II proposals will be accepted. Number of anticipated awards: 1-3 Budget (total costs): Phase I: $300,000/year for up to 2 years; Phase II: $1,000,000/year with appropriate justification by the applicant for up to 3 years. Background The goal of this program is to support the screening for new vaccine adjuvant candidates against infectious dise ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  3. NIH/NCI 445: ADVANCED MANUFACTURING TO SPEED AVAILABILITY OF EMERGING AUTOLOGOUS CELL-BASED THERAPIES

    Release Date: 07-12-2021Open Date: 07-12-2021Due Date: 10-28-2021Close Date: 10-28-2021

    Fast-Track proposals will be accepted. Direct-to-Phase II proposals will be accepted. Number of anticipated awards: 2-4 Budget (total costs, per award): Phase I: up to $400,000 for up to 12 months Phase II: up to $2,000,000 for up to 2 years PROPOSALS THAT EXCEED THE BUDGET OR PROJECT DURATION LISTED ABOVE MAY NOT BE FUNDED. Summary Page 95 Current manufacturing processes for autologous cell-based ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  4. NIH/NCI 439: ADVANCED SAMPLE PROCESSING PLATFORMS FOR DOWNSTREAM SINGLE-CELL MULTI-OMIC ANALYSIS

    Release Date: 07-12-2021Open Date: 07-12-2021Due Date: 10-28-2021Close Date: 10-28-2021

    Fast-Track proposals will NOT be accepted. Direct Phase II proposal will be accepted Number of anticipated awards: 3 - 5 Budget (total costs, per award): Phase I: up to $400,000 for up to 12 months Phase II: up to $2,000,000 for up to 2 years PROPOSALS THAT EXCEED THE BUDGET OR PROJECT DURATION LISTED ABOVE MAY NOT BE FUNDED. Summary Single cell multimodal omics (scMulti-omics) technologies by int ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  5. PAS-19-316 : Advancing Research on Alzheimer's Disease (AD) and Alzheimer's-Disease-Related Dementias (ADRD) (R43/R44 Clinical Trial Optional)

    Release Date: 07-18-2019Open Date: 12-05-2019 Due Dates: Multiple Close Date: 09-05-2022

    Recent recommendations and milestones for AD/ADRD research from the National Alzheimer’s Project Act, the 2015 Alzheimer’s Disease Research Summit, the 2018 Alzheimer’s Disease Research Summit, and the 2019 Alzheimer’s Disease and Related Dementias Research Summit present a wide range of research and development proposals which, if pursued, can reduce the human burden and healthcare costs ...

    SBIRPhase I/Phase IIDepartment of Health and Human Services
  6. PAS-19-317 : Advancing Research on Alzheimer's Disease (AD) and Alzheimer's-Disease-Related Dementias (ADRD) (R41/R42 Clinical Trial Optional)

    Release Date: 07-18-2019Open Date: 12-05-2019 Due Dates: Multiple Close Date: 09-05-2022

    Recent recommendations and milestones for AD/ADRD research from the National Alzheimer’s Project Act, the 2015 Alzheimer’s Disease Research Summit, the 2018 Alzheimer’s Disease Research Summit, and the 2019 Alzheimer’s Disease and Related Dementias Research Summit present a wide range of research and development proposals which, if pursued, can reduce the human burden and healthcare costs ...

    STTRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  7. RFA-DA-22-018: Advancing Validated Drug Targets for Substance Use Disorders (R41/R42- Clinical Trial Not Allowed)

    Release Date: 07-29-2021Open Date: 01-18-2022Due Date: 02-18-2022Close Date: 02-19-2022

    Background Substance use disorders (SUDs) affect people from all walks of life and all age groups. These illnesses are common, recurrent, and often serious, but they are treatable, and many people recover. SUDs occur when the recurrent use of drugs cause clinically significant impairment, including health problems, disability, and failure to meet major responsibilities at work, school, or home. T ...

    STTRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  8. RFA-DA-22-023: Advancing Validated Drug Targets for Substance Use Disorders (R43/R44- Clinical Trial Not Allowed)

    Release Date: 07-29-2021Open Date: 01-18-2022Due Date: 02-18-2022Close Date: 02-19-2022

    Background Substance use disorders (SUDs) affect people from all walks of life and all age groups. These illnesses are common, recurrent, and often serious, but they are treatable, and many people recover. SUDs occur when the recurrent use of drugs causes clinically significant impairment, including health problems, disability, and failure to meet major responsibilities at work, school, or home. ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  9. OSD213-008: Aim Augmentation for Small Caliber Weapons Systems

    Release Date: 08-25-2021Open Date: 09-21-2021Due Date: 10-21-2021Close Date: 10-21-2021

    The technology within this topic is restricted under the International Traffic in Arms Regulation (ITAR), 22 CFR Parts 120-130, which controls the export and import of defense-related material and services, including export of sensitive technical data, or the Export Administration Regulation (EAR), 15 CFR Parts 730-774, which controls dual use items. Offerors must disclose any proposed use of fore ...

    SBIRPhase I/Phase IIDepartment of DefenseOffice of the Secretary of Defense
  10. CDC/NCCDPHP 044: Algorithmic Database Food Product Tool to Align Food Service with Guidelines

    Release Date: 07-12-2021Open Date: 07-12-2021Due Date: 10-28-2021Close Date: 10-28-2021

    Phase I SBIR proposals will be accepted. Fast-Track proposals will not be accepted. Phase I clinical trials will not be accepted. Number of anticipated awards: 1 Budget (total costs): Phase I: up to $243,500 for up to 6 months; Phase II of up to $1,000,000 and a Phase II duration of up to 2 years PROPOSALS THAT EXCEED THE BUDGET OR PROJECT DURATION LISTED ABOVE MAY NOT BE FUNDED. Background Improv ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesCenters for Disease Control and Prevention
US Flag An Official Website of the United States Government